Vimarsana
Biggest News Aggregation in the World

Page 21 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

Health News Roundup: WHO asks countries to increase surveillance for Monkeypox; Senegal health minister sacked after babies die in hospital fire and more - Vimarsana News

Health News Roundup: WHO asks countries to increase surveillance for Monkeypox; Senegal health minister sacked after babies die in hospital fire and more

Testing and diagnosis rates for cancer dropped by 15% to 25% over the past two years as people skipped routine checkups, Dave Fredrickson, executive vice president of oncology at AstraZeneca, told the Reuters Global Markets Forum in Davos. WHO asks countries to increase surveillance for Monkeypox About 200 confirmed and more than 100 suspected cases of Monkeypox have been detected so far outside of the countries where it usually spreads, a World Health Organization official said on Thursday, urging countries to increase surveillance for the infectious disease.

ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with - Vimarsana News

ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with

Approval broadens indication for Daiichi Sankyo and AstraZeneca’s ENHERTU to earlier use in metastatic breast cancerBased on groundbreaking DESTINY-Breast03 results showing ENHERTU reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)...

ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen - Vimarsana News

ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
AstraZeneca, Merck get FDA approval for Lynparza to treat breast cancer - Vimarsana News

AstraZeneca, Merck get FDA approval for Lynparza to treat breast cancer

AstraZeneca and Merck have obtained the US Food and Drug Administration approval for Lynparza (olaparib) to treat early-stage breast cancer.

LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer - Vimarsana News

LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Mar 11, 2022--